Lilly’s manufacturing site in LEAP Lebanon, Indiana. Credit: PR Newswire / Eli Lilly and Company. Eli Lilly has announced a substantial increase in its manufacturing investment at its site in Lebanon, Indiana, US, committing an additional $5.3bn funding to enhance active pharmaceutical ingredients (API) manufacturing capacity. This brings the total investment to $9bn from $3.7bn,